All News

hands pregnant

Better Outcomes with Modern T2T in Pregnancy

Jack Cush, MD

With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.

Read Article
PSA2L.jpg

Progression from Psoriasis to Psoriatic Arthritis

Jack Cush, MD

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).

Read Article
yes, no, maybe

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Janet Pope, MD, MPH, FRCPC

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.

Read Article
meeting.audience.3.jpg

EULAR 2021 – Day 4 Report

Jack Cush, MD

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
unhappy%20patient.jpg

How do we personalize psoriatic arthritis treatment?

Robert Chao, MD

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
acr_session2.jpeg

EULAR 2021 – Day 2 Report

Jack Cush, MD

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein ejdein1 ( View Tweet)

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

Links:

Dr. John Cush RheumNow ( View Tweet)
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD AshimaMakol ( View Tweet)
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×